drugset / Trial / NCT01428479

Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Males

NCT01428479

Phase 1 Completed 18 enrolled GlaxoSmithKline
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study is a randomized, double-blind, ascending dose, placebo-controlled, incomplete crossover, single and multiple dose study in healthy Japanese male subjects to assess the pharmacokinetics and safety/tolerability of single and multiple intravenous administration of GR121167. Serial blood samples and pooled urine samples for the determination of GR121167 concentration will be collected and safety assessments will be performed for each treatment period. The pharmacokinetics and dose proportionality of GR121167 after single intravenous administration of GR121167 at the dose levels of 100 mg, 300 mg and 600 mg will be assessed. In addition, in the final treatment period (600 mg), twice daily intravenous administrations for 5 days will be also conducted and the pharmacokinetics and accumulation will be assessed.

Timeline

Start
2011-01-07
Primary completion
2011-04-04
Completion
2011-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanamivir Small molecule 100 mg Intravenous
Subject Zanamivir Small molecule 300 mg Intravenous
Subject Zanamivir Small molecule 600 mg Intravenous

Indications